RESEARCH ARTICLE SA JOURNAL OF DIABETES & VASCULAR DISEASE 30 VOLUME 21 NUMBER 1 • November 2024 44. Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur Heart J 2023; 44(39): 4043–4140. 45. Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol 2014; 64(5): 485–494. 46. McGinnis B, Olson KL, Magid D, Bayliss E, Korner EJ, Brand DW, et al. Factors related to adherence to statin therapy. Ann Pharmacother 2007; 41(11): 1805– 1811. 47. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; 160(14): 2101– 2107. 48. Blom DJ, Raal F, Amod A, Naidoo P, Lai YE. Management of lowdensity lipoprotein cholesterol levels in South Africa: the International ChoLesterol management Practice Study (ICLPS). Cardiovasc J Afr 2019; 30(1): 15–23. 49. Okerson T, Patel J, DiMario S, Burton T, Seare J, Harrison DJ. Effect of 2013 ACC/ AHA blood cholesterol guidelines on statin treatment patterns and low‐density lipoprotein cholesterol in atherosclerotic cardiovascular disease patients. J Am Heart Assoc 2017; 6(3): e004909. 50. Holland AT, Zhao B, Wong EC, Choi SE, Wong ND, Palaniappan LP. Racial/ethnic differences in control of cardiovascular risk factors among type 2 diabetes patients in an insured, ambulatory care population. J Diabetes Complicat 2013; 27(1): 34–40. 51. Bertoni AG, Clark JM, Feeney P, Yanovski SZ, Bantle J, Montgomery B, et al. Suboptimal control of glycemia, blood pressure, and LDL cholesterol in overweight adults with diabetes: the Look AHEAD Study. J Diabetes Complicat 2008; 22(1): 1–9. 52. Elis A, Rosenmann L, Chodick G, Heymann AD, Kokia E, Shalev V. The association between glycemic, lipids and blood pressure control among Israeli diabetic patients. Q J Med 2008; 101(4): 275–280. 53. Larry M, Alizadeh S, Naderi S, Salekani B, Mansournia MA, Rabizadeh S, et al. Inadequate achievement of ABC goals (HbA1c, blood pressure, LDL-C) among patients with type 2 diabetes in an Iranian population, 2012–2017. Diabetes Metabolic Syndr 2020; 14(4): 619–625. 54. Shah BM, Mezzio DJ, Ho J, Ip EJ. Association of ABC (HbA1c, blood pressure, LDL-cholesterol) goal attainment with depression and healthrelated quality of life among adults with type 2 diabetes. J Diabetes Complicat 2015; 29(6): 794–800. 55. Kitaoka K, Takenouchi A, Minato-Inokawa S, Takeuchi M, Tsuboi A, Kurata M, et al. Association of ABC (HbA1c, blood pressure and LDL-cholesterol) goal achievement with visit-to-visit ABC variability and postprandial dysmetabolism in type 2 diabetic patients. Asia Pacific J Clin Nutr 2020; 29(3): 476–482. 56. Pinchevsky Y, Shukla VJ, Butkow N, Chirwa T, Raal F. Multi-ethnic differences in HbA1c, blood pressure, and low-density-lipid cholesterol control among South Africans living with type 2 diabetes, after a 4-year follow-up. Int J Gen Med 2016; 9: 419. 57. Stern N, Marcus Y. Hypertension in diabetes: the role of the vasculature. Curr Hypertens Rep 2004; 6(2): 90–97. 58. Khunti K, Ceriello A, Cos X, De Block C. Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: A meta-analysis. Diabetes Res Clin Pract 2018; 137: 137–148. 59. Henein MY, Vancheri S, Longo G, Vancheri F. The role of inflammation in cardiovascular disease. Int J Molec Sci 2022; 23(21). 60. Guedeney P, Claessen BE, Kalkman DN, Aquino M, Sorrentino S, Giustino G, et al. Residual inflammatory risk in patients with low LDL cholesterol levels undergoing percutaneous coronary intervention. J Am Coll Cardiol 2019; 73(19): 2401–2409. 61. Ridker PM. How common is residual inflammatory risk? Cir Res 2017; 120(4): 617–619. 62. Chiu CJ, Wray LA. Factors predicting glycemic control in middle-aged and older adults with type 2 diabetes. Prevent Chronic Dis 2010; 7(1): A08. 63. Nichols GA, Hillier TA, Javor K, Brown JB. Predictors of glycemic control in insulinusing adults with type 2 diabetes. Diabetes Care 2000; 23(3): 273–277. 64. Chuang LM, Soegondo S, Soewondo P, Young-Seol K, Mohamed M, Dalisay E, et al. Comparisons of the outcomes on control, type of management and complications status in early onset and late onset type 2 diabetes in Asia. Diabetes Res Clin Pract 2006; 71(2): 146–155. 65. Lichtman JH, Bigger JT, Jr., Blumenthal JA, Frasure-Smith N, Kaufmann PG, Lespérance F, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation 2008; 118(17): 1768–1775. 66. De Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ. Association of depression and diabetes complications: a meta-analysis. Psychosomat Med 2001; 63(4): 619–630. 67. Ismail R, Csóka I. Novel strategies in the oral delivery of antidiabetic peptide drugs – Insulin, GLP 1 and its analogs. Euro J Pharmaceut Biopharmaceut 2017; 115: 257–267. 68. Wieczorek-Surdacka E, Surdacki A, Swierszcz J, Chyrchel B. Novel antidiabetic drugs in diabetic kidney disease accompanying type 2 diabetes – a minireview. Folia Medica Cracoviensia 2020; 60(4): 97–101. 69. Masson W, Lavalle-Cobo A, Lobo M, Masson G, Molinero G. Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis. Eur J Prevent Cardiol 2021; 28(1): 69–75. 70. Blum A. Freestyle Libre glucose monitoring system. Clin Diabetes 2018; 36(2): 203–204. 71. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139(25): e1082–e1143. 72. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br Med J 2003; 326(7404): 1423. 73. Lin EH, Rutter CM, Katon W, Heckbert SR, Ciechanowski P, Oliver MM, et al. Depression and advanced complications of diabetes: a prospective cohort study. Diabetes Care 2010; 33(2): 264–269. 74. Scherrer JF, Garfield LD, Chrusciel T, Hauptman PJ, Carney RM, Freedland KE, et al. Increased risk of myocardial infarction in depressed patients with type 2 diabetes. Diabetes Care 2011; 34(8): 1729–1734. 75. Ismail K, Moulton CD, Winkley K, Pickup JC, Thomas SM, Sherwood RA, et al. The association of depressive symptoms and diabetes distress with glycaemic control and diabetes complications over 2 years in newly diagnosed type 2 diabetes: a prospective cohort study. Diabetologia. 2017; 60(10): 2092–2102. 76. Taylor CB, Youngblood ME, Catellier D, Veith RC, Carney RM, Burg MM, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 2005; 62(7): 792–798. 77. Athyros VG, Katsiki N, Tziomalos K, Gossios TD, Theocharidou E, Gkaliagkousi E, et al. Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. Arch Med Sci 2013; 9(3): 418–426. 78. Sever PS, Poulter NR, Dahlöf B, Wedel H. Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOTLLA). Am J Cardiol 2005; 96(5a): 39f–44f. 79. Kones R. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease – a perspective. Drug Design Develop Ther 2010; 4: 383–413. 80. Redlich C, Berk M, Williams LJ, Sundquist J, Sundquist K, Li X. Statin use and risk of depression: a Swedish national cohort study. BMC Psychiatry 2014; 14: 348. 81. Kim JM, Stewart R, Kang HJ, Bae KY, Kim SW, Shin IS, et al. A prospective study of statin use and poststroke depression. J Clin Psychopharmacol 2014; 34(1): 72–79. 82. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundament Clin Pharmacol 2005; 19(1): 117–125. 83. Lustman PJ, Freedland KE, Griffith LS, Clouse RE. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care 2000; 23(5): 618–623. 84. Lustman PJ, Williams MM, Sayuk GS, Nix BD, Clouse RE. Factors influencing glycemic control in type 2 diabetes during acute- and maintenance-phase treatment of major depressive disorder with bupropion. Diabetes Care 2007; 30(3): 459–466. 85. Lloyd-Jones DM, Wilson PW, Larson MG, Beiser A, Leip EP, D’Agostino RB, et al. Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol 2004; 94(1): 20–24.
RkJQdWJsaXNoZXIy NDIzNzc=